Pegylated liposomal doxorubicin in ovarian cancer
Robert Strother1,2, Daniela Matei1–51Department of Medicine, 2Indiana University Melvin and Bren Simon Cancer Center, 3Department of Obstetrics and Gynecology, 4Department of Biochemistry and Molecular Biology, 5VA Roudebush Hospital Indiana University School of Medicine, 535 Barnhill Driv...
Saved in:
Main Authors: | Robert Strother (Author), Daniela Matei (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pegylated liposomal doxorubicin in the management of ovarian cancer
by: Gabriella Ferrandina, et al.
Published: (2010) -
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021) -
Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004) -
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
by: Xin-Ru Li, et al.
Published: (2022) -
Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016)